We are live on ! Find out more
BMRN icon

BioMarin Pharmaceuticals
BMRN

414 hedge funds and large institutions have $14B invested in BioMarin Pharmaceuticals in 2016 Q4 according to their latest regulatory filings, with 57 funds opening new positions, 159 increasing their positions, 150 reducing their positions, and 57 closing their positions.

New
Increased
Maintained
Reduced
Closed

98.49% more ownership

Funds ownership: 0% → 98.49% (+98%)

6% more repeat investments, than reductions

Existing positions increased: 159 | Existing positions reduced: 150

0% more first-time investments, than exits

New positions opened: 57 | Existing positions closed: 57

5% less call options, than puts

Call options by funds: $90.6M | Put options by funds: $95.7M

2% less funds holding

Funds holding: 422 → 414 (-8)

9% less capital invested

Capital invested by funds: $15.4B → $14B (-$1.35B)

15% less funds holding in top 10

Funds holding in top 10: 13 → 11 (-2)

Holders
414
Holders Change
-8
Holders Change %
-1.9%
% of All Funds
10.35%
Holding in Top 10
11
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-15.38%
% of All Funds
0.28%
New
57
Increased
159
Reduced
150
Closed
57
Calls
$90.6M
Puts
$95.7M
Net Calls
-$5.06M
Net Calls Change
-$8.09M

Top Buyers

1
MNA
Manning & Napier Advisors
New York
+$162M
2
Vanguard Group
Vanguard Group
Pennsylvania
+$84M
3
Viking Global Investors
Viking Global Investors
Connecticut
+$78.1M
4
Primecap Management
Primecap Management
California
+$66.9M
5
HM
HealthCor Management
New York
+$66.6M

Top Sellers

1
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$120M
2
Fidelity Investments
Fidelity Investments
Massachusetts
-$102M
3
Sands Capital Management
Sands Capital Management
Virginia
-$72.3M
4
Capital Research Global Investors
Capital Research Global Investors
California
-$49.3M
5
FAM
Fred Alger Management
New York
-$48.1M
Name Holding Trade Value Shares
Change 		Change in
Stake
CHP
301
Cable Hill Partners
Oregon
$364K – – –
GAM
302
Gemmer Asset Management
California
$360K +$310K +3,600 +480%
Daiwa Securities Group
303
Daiwa Securities Group
Japan
$356K +$43K +500 +13%
OMCS
304
Old Mutual Customised Solutions
South Africa
$356K +$163K +1,900 +79%
GCA
305
Greenwood Capital Associates
South Carolina
$355K -$20.6K -240 -5%
ANRIA
306
American National Registered Investment Advisor
Texas
$355K – – –
MNBTD
307
Moody National Bank Trust Division
Texas
$350K – – –
MSV
308
MN Services Vermogensbeheer
Netherlands
$347K +$22.4K +260 +6%
HPCM
309
High Pointe Capital Management
Illinois
$345K – – –
CCM
310
Catawba Capital Management
Virginia
$344K +$61.5K +715 +21%
PCA
311
Private Capital Advisors
Connecticut
$331K +$344K +4,000 New
CL
312
CSS LLC
Illinois
$320K +$55.9K +650 +20%
SBA
313
Seven Bridges Advisors
New York
$319K +$1.12K +13 +0.3%
RJFSA
314
Raymond James Financial Services Advisors
Florida
$317K -$340K -3,958 -51%
WSA
315
Wall Street Associates
California
$311K -$602 -7 -0.2%
PAG
316
Private Advisor Group
New Jersey
$300K +$75.4K +877 +33%
AG
317
Advisor Group
Arizona
$298K +$26.6K +309 +9%
RIM
318
Regent Investment Management
Kentucky
$280K -$6.45K -75 -2%
ECM
319
ETrade Capital Management
Virginia
$277K -$48.8K -568 -15%
NFG
320
Next Financial Group
Texas
$275K +$30.1K +350 +12%
EOJOAM
321
E. Ohman J:or Asset Management
Sweden
$273K – – –
FP
322
Foundry Partners
Minnesota
$269K +$279K +3,242 New
DWA
323
Douglass Winthrop Advisors
New York
$258K – – –
NI
324
Numeric Investors
Massachusetts
$257K -$1.57M -18,300 -86%
AIP
325
Ameritas Investment Partners
Nebraska
$254K – – –
11 12
13
14 15

BMRN Hedge Fund Activity: Q4 2016 in Review

414 of the 4,000 institutional investors tracked by Wall St. Rank reported a position in BioMarin Pharmaceuticals (BMRN) for Q4 2016, worth a combined $14B — down 8.8% from $15.4B a quarter earlier.

Fund positioning in BMRN was balanced in Q4 2016: 57 funds opened new positions, 57 closed out, 159 added to existing stakes and 150 trimmed.

The largest buyer was Manning & Napier Advisors, adding an estimated $162M. The largest seller was T. Rowe Price Associates, cutting an estimated $120M.

  • 414 institutional investors held BioMarin Pharmaceuticals (BMRN) as of Q4 2016, down from 422 in Q3 2016.
  • Funds reported $14B of BioMarin Pharmaceuticals stock for Q4 2016, down 8.8% quarter-over-quarter.
  • 57 funds opened new BioMarin Pharmaceuticals positions in Q4 2016 and 57 closed out, a net change of 0 holders.
  • The largest BioMarin Pharmaceuticals buyer in Q4 2016 was Manning & Napier Advisors, an estimated $162M added.
  • The largest BioMarin Pharmaceuticals seller in Q4 2016 was T. Rowe Price Associates, an estimated $120M sold.

Based on aggregated 13F filings for Q4 2016.